Maki Yoshino, Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi, Takashi Ikeda, Takayuki Nakayama, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hiroaki Shimmura, et al. Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma. Targeted oncology. 2024. 19. 4. 623-633
Hiroki Ishihara, Nemoto Yuki, Ryo Ishiyama, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, Hiroaki Shimmura, Yasunobu Hashimoto, Junpei Iizuka, et al. Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. Japanese journal of clinical oncology. 2024. 54. 5. 577-583
Hiroki Ishihara, Kenji Omae, Yuki Nemoto, Ryo Ishiyama, Hidekazu Tachibana, Koichi Nishimura, Takashi Ikeda, Yuki Kobari, Hironori Fukuda, Kazuhiko Yoshida, et al. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data. International journal of clinical oncology. 2024
Hiroki Ishihara, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Yoji Nagashima, Tsunenori Kondo, Toshio Takagi. Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. International journal of urology : official journal of the Japanese Urological Association. 2023
